Form D · Biotechnology
OncoNano Medicine, Inc.
Dallas, TX · CIK 0001735726
Offering snapshot reported Oct 8, 2026 · SEC filing
- Reported sold
- $10.1M Offering amount: $15M
- Investors reported
- 14 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 23, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 8, 2026 | Initial | $10,051,615 | No comparison | 14 | SEC filing |
| Jun 2, 2025 | Initial | $12,698,061 | No comparison | 25 | SEC filing |
| Nov 3, 2021 | Amendment | $68,407,469 | $19,344,747vs Jun 17, 2021 | 27 | SEC filing |
| Jun 17, 2021 | Amendment | $49,062,722 | $27,595,570vs Oct 21, 2020 | 25 | SEC filing |
| Mar 26, 2021 | Amendment | $26,425,222 | $4,958,070vs Oct 21, 2020 | 24 | SEC filing |
| Oct 21, 2020 | Initial | $21,467,152 | No comparison | 21 | SEC filing |
| Apr 22, 2019 | Amendment | $33,899,361 | $22,240,835vs Mar 28, 2018 | 39 | SEC filing |
| Mar 28, 2018 | Initial | $11,658,526 | No comparison | 27 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $402K (estimated)
- Finders' fees
- $0
- Form D file number
- 021-600468
The broker earned $402,065 in cash and will earn a (1) 4.0% cash fee on any later sales and (2) warrant to purchase shares of common stock equal to 4% of the aggregate number of shares sold in the transaction.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Salem Partners LLC | 43363 |
Source: Form D, filed Oct 8, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Paritosh Dhawale | Director |
| Martin Driscoll | Director, Executive |
| John Dyett | Director |
| Brett Giroir | Director, Executive |
| Joydeep Goswami | Director |
| Alvaro Guillem | Director |
| Matthew Head | Executive |
| Gina Jones | Director |
| Jeff Keyser | Executive |
| Kartik Krishnan | Director, Executive |
| Melissa Paoloni | Executive |
| Yumin Qiu | Director |
| Yumin Qui | Director |
| Caleb Smith | Director |
| Brent Sorrells | Executive |
| Ravi Srinivasan | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
3060 Pegasus Park Drive
Dallas, TX, 75247
Phone: 682-285-1411
Dallas, TX, 75247
Phone: 682-285-1411